BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

447 related articles for article (PubMed ID: 23670175)

  • 21. Role of JAK inhibitors in myeloproliferative neoplasms: current point of view and perspectives.
    Loscocco GG; Vannucchi AM
    Int J Hematol; 2022 May; 115(5):626-644. PubMed ID: 35352288
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular pathways: Jak/STAT pathway: mutations, inhibitors, and resistance.
    Quintás-Cardama A; Verstovsek S
    Clin Cancer Res; 2013 Apr; 19(8):1933-40. PubMed ID: 23406773
    [TBL] [Abstract][Full Text] [Related]  

  • 23. mTOR inhibitors alone and in combination with JAK2 inhibitors effectively inhibit cells of myeloproliferative neoplasms.
    Bogani C; Bartalucci N; Martinelli S; Tozzi L; Guglielmelli P; Bosi A; Vannucchi AM;
    PLoS One; 2013; 8(1):e54826. PubMed ID: 23382981
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel myelofibrosis treatment strategies: potential partners for combination therapies.
    Stein BL; Swords R; Hochhaus A; Giles F
    Leukemia; 2014 Nov; 28(11):2139-47. PubMed ID: 24888274
    [TBL] [Abstract][Full Text] [Related]  

  • 25. JAK inhibition in the myeloproliferative neoplasms: lessons learned from the bench and bedside.
    Gotlib J
    Hematology Am Soc Hematol Educ Program; 2013; 2013():529-37. PubMed ID: 24319228
    [TBL] [Abstract][Full Text] [Related]  

  • 26. JAK2 the future: therapeutic strategies for JAK-dependent malignancies.
    LaFave LM; Levine RL
    Trends Pharmacol Sci; 2012 Nov; 33(11):574-82. PubMed ID: 22995223
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Guidelines for the management of myeloproliferative neoplasms.
    Choi CW; Bang SM; Jang S; Jung CW; Kim HJ; Kim HY; Kim SJ; Kim YK; Park J; Won JH
    Korean J Intern Med; 2015 Nov; 30(6):771-88. PubMed ID: 26552452
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New JAK2 inhibitors for myeloproliferative neoplasms.
    Quintás-Cardama A; Verstovsek S
    Expert Opin Investig Drugs; 2011 Jul; 20(7):961-72. PubMed ID: 21521147
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recent patents of gene mutation relative to JAK/STAT pathway and their implication in myeloproliferative diseases.
    Shi Y; Xu C
    Recent Pat DNA Gene Seq; 2008; 2(3):209-13. PubMed ID: 19075958
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Novel therapeutics in myeloproliferative neoplasms: beyond JAK inhibitors].
    Edahiro Y
    Rinsho Ketsueki; 2023; 64(9):970-980. PubMed ID: 37793873
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms.
    Quintás-Cardama A; Vaddi K; Liu P; Manshouri T; Li J; Scherle PA; Caulder E; Wen X; Li Y; Waeltz P; Rupar M; Burn T; Lo Y; Kelley J; Covington M; Shepard S; Rodgers JD; Haley P; Kantarjian H; Fridman JS; Verstovsek S
    Blood; 2010 Apr; 115(15):3109-17. PubMed ID: 20130243
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Myeloproliferative and lymphoproliferative disorders: State of the art.
    Rumi E; Baratè C; Benevolo G; Maffioli M; Ricco A; Sant'Antonio E
    Hematol Oncol; 2020 Apr; 38(2):121-128. PubMed ID: 31833567
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors.
    Choong ML; Pecquet C; Pendharkar V; Diaconu CC; Yong JW; Tai SJ; Wang SF; Defour JP; Sangthongpitag K; Villeval JL; Vainchenker W; Constantinescu SN; Lee MA
    J Cell Mol Med; 2013 Nov; 17(11):1397-409. PubMed ID: 24251790
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Emerging targeted therapies in myelofibrosis.
    Barosi G
    Expert Rev Hematol; 2012 Jun; 5(3):313-24. PubMed ID: 22780211
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular pathways: molecular basis for sensitivity and resistance to JAK kinase inhibitors.
    Meyer SC; Levine RL
    Clin Cancer Res; 2014 Apr; 20(8):2051-9. PubMed ID: 24583800
    [TBL] [Abstract][Full Text] [Related]  

  • 36. JAK2 inhibitor persistence in MPN: uncovering a central role of ERK activation.
    Pandey G; Kuykendall AT; Reuther GW
    Blood Cancer J; 2022 Jan; 12(1):13. PubMed ID: 35082276
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of JAK pathway dysregulation in the pathogenesis and treatment of acute myeloid leukemia.
    Lee HJ; Daver N; Kantarjian HM; Verstovsek S; Ravandi F
    Clin Cancer Res; 2013 Jan; 19(2):327-35. PubMed ID: 23209034
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapy with JAK2 inhibitors for myeloproliferative neoplasms.
    Santos FP; Verstovsek S
    Hematol Oncol Clin North Am; 2012 Oct; 26(5):1083-99. PubMed ID: 23009939
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cotargeting the JAK/STAT signaling pathway and histone deacetylase by ruxolitinib and vorinostat elicits synergistic effects against myeloproliferative neoplasms.
    Hao X; Xing W; Yuan J; Wang Y; Bai J; Bai J; Zhou Y
    Invest New Drugs; 2020 Jun; 38(3):610-620. PubMed ID: 31227936
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Should we be treating lower risk myelofibrosis patients with a JAK2 inhibitor?
    Lancman G; Mascarenhas J
    Expert Rev Hematol; 2017 Jan; 10(1):23-28. PubMed ID: 27882812
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.